Heparin Sodium Cleared: FDA Okays Generic Blood Thinner Options
Published Date: 8/26/2025
Notice
Summary
The FDA says four types of heparin sodium in plastic containers weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now get approval to sell their versions, helping hospitals and patients get more options. No extra costs or delays are expected, so everyone wins!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ANDA Approvals Allowed for Heparin Products
The FDA determined four heparin sodium products (listed under NDA 019802) were not withdrawn for safety or effectiveness. This determination lets the FDA approve abbreviated new drug applications (ANDAs) that refer to these products if all other legal and regulatory requirements are met.
More Heparin Options for Hospitals and Patients
Because the FDA found these four heparin sodium products were not withdrawn for safety or effectiveness, generic versions can be approved. The notice says this can help hospitals and patients get more options and that no extra costs or delays are expected.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in